Horizon Therapeutics (United States)

Horizon Therapeutics, now part of Amgen, developed treatments for rare autoimmune and inflammatory diseases. Key products include Tepezza (teprotumumab) for thyroid eye disease (Graves’ orbitopathy), Krystexxa (pegloticase) for uncontrolled gout, and Uplizna (inebilizumab) for neuromyelitis optica. Horizon’s rare disease expertise continues advancing treatments through Amgen’s biopharmaceutical portfolio.